Beam Therapeutics Inc
BEAM
26.40USD-2.35Â (-8.17%)Market ClosedWatchlist
Market Summary
USD26.40-2.35
Market Closed-8.17%
BEAM Stock Price
View Fullscreen
BEAM RSI Chart
BEAM Valuation
BEAM Price/Sales (Trailing)
BEAM Profitability
BEAM Fundamentals
BEAM Revenue
BEAM Earnings
Price Action
Last 7 days
2.4%
Last 30 days
15.1%
Last 90 days
12.5%
Trailing 12 Months
-34.8%
How does BEAM drawdown profile look like?
BEAM Financial Health
BEAM Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 76.7M | 80.2M | 81.6M | 0 |
| 2022 | 54.1M | 56.4M | 58.7M | 60.9M |
| 2021 | 13.0M | 25.9M | 38.9M | 51.8M |
| 2020 | 0 | 0 | 0 | 24.0K |
| 2019 | 0 | 0 | 0 | 0 |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for BEAM
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 20, 2023 | bellon christine | sold | -305,000 | 30.5 | -10,000 | chief legal officer |
| Nov 20, 2023 | bellon christine | acquired | 72,200 | 7.22 | 10,000 | chief legal officer |
| Oct 30, 2023 | simon amy | sold | -64,477 | 18.7 | -3,448 | chief medical officer |
| Oct 20, 2023 | ciaramella giuseppe | acquired | 60,903 | 0.67 | 90,900 | president and cso |
| Oct 02, 2023 | bellon christine | sold | -8,865 | 22.85 | -388 | chief legal officer |
| Jul 24, 2023 | ciaramella giuseppe | sold | -38,604 | 32.01 | -1,206 | president and cso |
| Jul 24, 2023 | ciaramella giuseppe | acquired | 8,707 | 7.22 | 1,206 | president and cso |
| Jul 21, 2023 | ciaramella giuseppe | sold | -4,979,690 | 32.06 | -155,324 | president and cso |
| Jul 21, 2023 | ciaramella giuseppe | acquired | 659,070 | 7.22 | 91,284 | president and cso |
| Jul 10, 2023 | simon amy | sold | -11,917 | 30.48 | -391 | chief medical officer |
Which funds bought or sold BEAM recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | added | 21.48 | -441,334 | 4,752,210 | -% |
| Nov 27, 2023 | AllSquare Wealth Management LLC | reduced | -78.57 | -14,978 | 2,886 | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 8.36 | -307,690 | 1,366,020 | -% |
| Nov 21, 2023 | COMERICA BANK | new | - | 12,939 | 12,939 | -% |
| Nov 16, 2023 | Financial Gravity Asset Management, Inc. | sold off | -100 | -31.00 | - | -% |
| Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | new | - | 283,000 | 283,000 | 0.02% |
| Nov 15, 2023 | MORGAN STANLEY | reduced | -37.48 | -14,110,500 | 12,557,200 | -% |
| Nov 15, 2023 | Beaird Harris Wealth Management, LLC | reduced | -49.76 | -4,188 | 2,550 | -% |
| Nov 15, 2023 | Baker Avenue Asset Management, LP | added | 26.09 | -37.00 | 697 | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 22.29 | -69,070 | 806,036 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Beam Therapeutics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 22, 2023 | farallon capital partners, l.p. | 0.4% | 306,547 | SC 13G | |
| Mar 17, 2023 | temasek holdings (private) ltd | 5.0% | 3,644,573 | SC 13G | |
| Feb 14, 2023 | farallon capital partners, l.p. | 0.0% | 0 | SC 13G/A | |
| Feb 10, 2023 | temasek holdings (private) ltd | 4.1% | 2,878,297 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.90% | 6,273,630 | SC 13G/A | |
| Feb 02, 2023 | blackrock inc. | 7.4% | 5,238,280 | SC 13G/A | |
| Jul 14, 2022 | farallon capital partners, l.p. | 0.4% | 276,948 | SC 13G | |
| Feb 14, 2022 | arch venture fund ix, l.p. | 8.6% | 5,843,039 | SC 13G/A | |
| Feb 14, 2022 | redmile group, llc | 2.8% | 1,885,850 | SC 13G/A |
Recent SEC filings of Beam Therapeutics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 22, 2023 | 4 | Insider Trading | |
| Nov 20, 2023 | 144 | Notice of Insider Sale Intent | |
| Nov 08, 2023 | 8-K | Current Report | |
| Nov 08, 2023 | 10-Q | Quarterly Report | |
| Nov 01, 2023 | 4 | Insider Trading | |
| Oct 31, 2023 | 8-K | Current Report | |
| Oct 30, 2023 | 144 | Notice of Insider Sale Intent | |
| Oct 24, 2023 | 4 | Insider Trading | |
| Oct 19, 2023 | 8-K | Current Report | |
| Oct 12, 2023 | UPLOAD | UPLOAD |
Peers (Alternatives to Beam Therapeutics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 5.25% | 401813.88% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 8.54% | -55.34% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 4.15% | -23.37% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 11.05% | -8.44% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 0.84% | -34.33% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 35.37% | 34.74% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 14.36% | 263.35% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -7.32% | 48.57% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.28% | -10.13% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -10.83% | -25.35% | -12.52 | 10.67 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 11.36% | -14.92% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -22.00% | -67.89% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.23% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 376.67% | 112.17% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 25.24% | 3980.68% | -0.5 | - | - | -13.74% |
Beam Therapeutics Inc News
Latest updates
Financials for Beam Therapeutics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Revenue | -14.5% | 17,193,000 | 20,116,000 | 24,208,000 | 20,037,000 | 15,799,000 | 16,652,000 | 8,432,000 | 6,325,500 | 4,219,000 | 2,112,500 | 6,000 | 6,000 | 6,000 | 162,800 | 319,600 | 476,400 | 633,200 | 790,000 | 498,000 |
| Operating Expenses | 2.6% | 125,460,000 | 122,264,000 | 123,136,000 | 109,022,000 | 107,102,000 | 98,618,000 | 84,657,000 | 114,553,000 | 70,397,000 | 58,980,000 | 200,379,000 | 40,805,000 | 37,327,000 | 26,291,000 | 28,361,000 | 26,377,000 | 18,030,000 | 17,657,000 | 13,108,000 |
| S&GA Expenses | 3.1% | 25,410,000 | 24,656,000 | 23,490,000 | 22,681,000 | 21,815,000 | 24,062,000 | 19,247,000 | 17,772,000 | 15,774,000 | 13,403,000 | 10,273,000 | 8,354,000 | 7,502,000 | 6,937,000 | 6,812,000 | 6,160,000 | 5,487,000 | 4,977,000 | 3,929,000 |
| R&D Expenses | 2.5% | 100,050,000 | 97,608,000 | 99,646,000 | 86,341,000 | 85,287,000 | 74,556,000 | 65,410,000 | 96,781,000 | 54,623,000 | 45,577,000 | 190,106,000 | 32,451,000 | 29,825,000 | 19,354,000 | 21,549,000 | 20,217,000 | 12,543,000 | 12,680,000 | 9,179,000 |
| EBITDA Margin | - | - | - | -3.19 | -4.03 | -4.77 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Expenses | -44.0% | 28,000 | 50,000 | 62,000 | 76,000 | 86,000 | 101,000 | 113,000 | 124,000 | 136,000 | 148,000 | 159,000 | 139,000 | 140,000 | - | - | - | - | - | - |
| Income Taxes | - | - | - | - | 1,010,000 | 2,410,000 | - | - | - | - | - | 159,000 | -422,000 | 140,000 | 148,000 | 134,000 | - | - | - | - |
| Earnings Before Taxes | - | - | - | - | -37,349,000 | -81,665,000 | - | - | -64,707,000 | -28,118,000 | - | - | - | - | - | - | - | - | - | - |
| EBT Margin | - | - | - | -3.39 | -4.27 | -4.99 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -16.1% | -96,088,000 | -82,776,000 | -96,460,000 | -38,349,000 | -109,575,000 | -71,950,000 | -69,214,000 | -64,707,000 | -28,118,000 | -76,253,000 | -201,560,000 | -95,464,000 | -34,452,000 | -34,218,000 | -30,458,000 | -27,850,000 | -19,005,000 | -17,861,000 | -13,610,000 |
| Net Income Margin | 100.0% | - | -4.08 | -4.12 | -4.75 | -5.38 | -4.51 | -4.60 | -7.15 | -10.32 | -15.72 | -28.18 | -8,108 | -282 | -127 | -73.21 | - | - | - | - |
| Free Cashflow | 100.0% | - | -100,847,000 | -115,832,000 | -77,452,000 | -86,283,000 | -73,920,000 | 211,231,000 | -11,539,000 | -2,773,000 | -48,711,000 | -50,056,000 | -32,423,000 | -24,032,000 | -25,204,000 | -30,439,000 | -19,960,000 | -18,411,000 | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 |
| Assets | -4.7% | 1,291 | 1,354 | 1,332 | 1,342 | 1,350 | 1,418 | 1,453 | 1,474 | 1,157 | 893 | 693 | 452 | 278 | 300 | 323 | 156 |
| Current Assets | -5.0% | 1,040 | 1,095 | 1,083 | 1,093 | 1,109 | 1,180 | 1,239 | 1,273 | 941 | 678 | 515 | 308 | 209 | 235 | 260 | 95.00 |
| Cash Equivalents | -21.2% | 178 | 226 | 250 | 233 | 157 | 266 | 297 | 573 | 612 | 212 | 97.00 | 162 | 138 | 125 | 126 | 51.00 |
| Net PPE | -0.5% | 128 | 128 | 122 | 116 | 111 | 106 | 94.00 | 84.00 | 72.00 | 64.00 | 52.00 | 39.00 | 29.00 | 26.00 | 25.00 | 24.00 |
| Liabilities | -5.7% | 512 | 542 | 571 | 608 | 636 | 618 | 624 | 648 | 303 | 345 | 271 | 206 | 78.00 | 69.00 | 61.00 | 55.00 |
| Current Liabilities | 5.2% | 220 | 210 | 220 | 224 | 239 | 212 | 219 | 213 | 101 | 129 | 102 | 102 | 47.00 | 39.00 | 31.00 | 29.00 |
| Shareholder's Equity | -4.0% | 779 | 812 | 762 | 733 | 714 | 800 | 829 | 827 | 854 | 549 | 422 | 246 | 200 | 231 | 261 | - |
| Retained Earnings | -8.3% | -1,300 | -1,200 | -1,153 | -1,057 | -1,019 | -909 | -837 | -768 | -703 | -675 | -599 | -397 | -302 | -267 | -233 | -203 |
| Additional Paid-In Capital | 3.1% | 2,113 | 2,049 | 1,915 | 1,793 | 1,737 | 1,713 | 1,669 | 1,594 | 1,557 | 1,223 | 1,021 | 643 | 502 | 498 | 495 | 2.00 |
| Shares Outstanding | 1.8% | 79.00 | 78.00 | 74.00 | 71.00 | 70.00 | 70.00 | 69.00 | 68.00 | 66.00 | 62.00 | 60.00 | 57.00 | 50.00 | 49.00 | 31.00 | 7.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Millions) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
| Cashflow From Operations | -6.0% | -89.78 | -84.67 | -109 | -69.19 | -74.50 | -52.28 | 218 | 2.00 | 3.00 | -32.53 | -38.58 | -24.30 | -21.21 | -22.84 | -27.39 | -17.80 | -16.99 | -11.35 | -25.86 |
| Share Based Compensation | -1.7% | 26.00 | 26.00 | 24.00 | 22.00 | 22.00 | 22.00 | 18.00 | 16.00 | 13.00 | 10.00 | 5.00 | 7.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.00 |
| Cashflow From Investing | 75.3% | -10.23 | -41.48 | 25.00 | 113 | -36.17 | -1.26 | -537 | -77.50 | 76.00 | -13.14 | -279 | -81.43 | 35.00 | 23.00 | -76.79 | 17.00 | 14.00 | -95.08 | -2.35 |
| Cashflow From Financing | -65.8% | 37.00 | 108 | 98.00 | 32.00 | 2.00 | 22.00 | 56.00 | 22.00 | 321 | 160 | 253 | 130 | 0.00 | -0.78 | 193 | 1.00 | 3.00 | -0.02 | 38.00 |
BEAM Income Statement
2023-09-30Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Income Statement [Abstract] | ||||
| License and collaboration revenue | $ 17,193,000 | $ 15,799,000 | $ 61,517,000 | $ 40,883,000 |
| Revenue, Product and Service [Extensible List] | us-gaap:LicenseMember | us-gaap:LicenseMember | us-gaap:LicenseMember | us-gaap:LicenseMember |
| Operating expenses: | ||||
| Research and development | $ 100,050,000 | $ 85,287,000 | $ 297,304,000 | $ 225,253,000 |
| General and administrative | 25,410,000 | 21,815,000 | 73,556,000 | 65,124,000 |
| Total operating expenses | 125,460,000 | 107,102,000 | 370,860,000 | 290,377,000 |
| Loss from operations | (108,267,000) | (91,303,000) | (309,343,000) | (249,494,000) |
| Other income (expense): | ||||
| Change in fair value of derivative liabilities | 4,700,000 | (4,900,000) | 9,400,000 | 20,900,000 |
| Change in fair value of non-controlling equity investments | (11,221,000) | 10,431,000 | (17,870,000) | (1,378,000) |
| Change in fair value of contingent consideration liabilities | 6,002,000 | (875,000) | 7,877,000 | (543,000) |
| Interest and other income (expense), net | 12,698,000 | 4,982,000 | 34,612,000 | 7,686,000 |
| Total other income (expense) | 12,179,000 | 9,638,000 | 34,019,000 | 26,665,000 |
| Net loss before income taxes | (96,088,000) | (81,665,000) | (275,324,000) | (222,829,000) |
| Provision for income taxes | 0 | (2,410,000) | 0 | (2,410,000) |
| Loss from equity method investment | (25,500,000) | (25,500,000) | ||
| Net loss | (96,088,000) | (109,575,000) | (275,324,000) | (250,739,000) |
| Unrealized gain (loss) on marketable securities | (9,000) | (484,000) | 406,000 | (4,624,000) |
| Comprehensive loss | $ (96,097,000) | $ (110,059,000) | $ (274,918,000) | $ (255,363,000) |
| Net loss per common share, basic | $ (1.22) | $ (1.56) | $ (3.63) | $ (3.59) |
| Net loss per common share, diluted | $ (1.22) | $ (1.56) | $ (3.63) | $ (3.59) |
| Weighted - average common shares outstanding, basic | 79,024,647 | 70,343,196 | 75,902,612 | 69,758,434 |
| Weighted - average common shares outstanding, diluted | 79,024,647 | 70,343,196 | 75,902,612 | 69,758,434 |
BEAM Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 169,049 | $ 232,767 |
| Marketable securities | 846,408 | 845,367 |
| Prepaid expenses and other current assets | 24,084 | 14,762 |
| Total current assets | 1,039,541 | 1,092,896 |
| Property and equipment, net | 127,521 | 115,620 |
| Restricted cash | 8,680 | 12,754 |
| Operating lease right-of-use assets | 112,140 | 118,513 |
| Other assets | 2,652 | 1,931 |
| Total assets | 1,290,534 | 1,341,714 |
| Current liabilities: | ||
| Accounts payable | 3,177 | 9,029 |
| Accrued expenses and other current liabilities | 41,769 | 48,059 |
| Derivative liabilities | 8,900 | 18,300 |
| Current portion of deferred revenue | 153,484 | 135,974 |
| Current portion of lease liability | 11,951 | 10,380 |
| Current portion of equipment financing liability | 1,084 | 1,853 |
| Total current liabilities | 220,365 | 223,595 |
| Long-term lease liability | 160,637 | 168,625 |
| Long-term equipment financing liability | 304 | 1,154 |
| Contingent consideration liabilities | 4,586 | 12,463 |
| Long-term portion of deferred revenue | 124,653 | 202,179 |
| Other liabilities | 1,048 | 224 |
| Total liabilities | 511,593 | 608,240 |
| Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at September 30, 2023 and December 31, 2022, respectively | ||
| Common stock, $0.01 par value; 250,000,000 shares authorized, 79,382,032 and 71,277,339 issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 794 | 712 |
| Additional paid-in capital | 2,112,857 | 1,792,554 |
| Accumulated other comprehensive (loss) income | (2,024) | (2,430) |
| Accumulated deficit | (1,332,686) | (1,057,362) |
| Total stockholders' equity | 778,941 | 733,474 |
| Total liabilities and stockholders' equity | $ 1,290,534 | $ 1,341,714 |
| Â CEO | Mr. John M. Evans M.B.A. |
|---|---|
| Â WEBSITE | beamtx.com |
| Â EMPLOYEES | 532 |